Theseus Pharmaceuticals, Inc.
NASDAQ:THRX
4.065 (USD) • At close February 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.438 | 0.002 | 0.002 | 0.002 |
| Gross Profit
| -0.438 | -0.002 | -0.002 | -0.002 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 35.698 | 18.328 | 5.958 | 4.124 |
| General & Administrative Expenses
| 18.388 | 9.008 | 0.878 | 0.818 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 |
| SG&A
| 18.388 | 9.008 | 0.878 | 0.818 |
| Other Expenses
| 3.478 | 0.028 | -5.161 | -2.241 |
| Operating Expenses
| 54.086 | 27.336 | 6.836 | 4.942 |
| Operating Income
| -54.086 | -27.336 | -6.836 | -4.942 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.478 | 0.028 | -5.161 | -2.241 |
| Income Before Tax
| -50.608 | -27.308 | -11.997 | -7.183 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 |
| Income Tax Expense
| -3.528 | 0 | 0 | 0 |
| Net Income
| -47.08 | -27.308 | -11.997 | -7.183 |
| Net Income Ratio
| 0 | 0 | 0 | 0 |
| EPS
| -1.22 | -2.84 | -0.47 | -0.6 |
| EPS Diluted
| -1.22 | -2.84 | -0.47 | -0.6 |
| EBITDA
| -54.086 | -27.334 | -6.834 | -4.94 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 |